Showing 20 search results
AAT Deficiency Screening Guidelines
Alpha-1 antitrypsin (AAT) deficiency testing guidelines from COPD Foundation, ATS, GOLD, WHO and CHEST.
Contact us for more information about AlphaID™ screening test and alpha-1 antitrypsin deficiency.
Pathophysiology of AAT Deficiency
Causes of alpha-1 antitrypsin (AAT) deficiency and the disordered physiological processes associated with this genetic form of COPD.
AlphaID™ Screening Test Fit into my Practice
Diagnosing alpha-1 antitrypsin (AAT) deficiency has evolved to become relatively simple, in two steps; screening test and diagnosis test.
Order form to request free AlphaID™ genetic screening test kits for alpha-1 antitrypsin (AAT) deficiency.
Order form to request free AlphaID™ genetic screening test kits for alpha-1 antitrypsin (AAT) deficiency.
Advocacy & Professional Organizations
Useful links to the major clinical organizations and foundations for further information and support about alpha-1 antitrypsin (AAT) deficiency and COPD.
Discover what the benefits of an early diagnosis of AAT deficiency are.
Benefits of increasing detection and early diagnosis of AAT deficiency
Discover what the benefits of an early diagnosis of AAT deficiency are.
Alpha-1 antitrypsin (AAT) deficiency shares signs and symptoms with COPD (which includes emphysema, asthma and chronic bronchitis). Individuals may wait 8 years to get diagnosed.
AAT Deficiency Inheritance Pattern
The most common genotypes, AAT serum levels, and risk for AAT deficiency. See alpha-1 family tree and learn how is alpha-1 inherited
Frequently asked questions about alpha-1 antitrypsin deficiency, its connection with COPD, disease diagnosis, screening guidelines and more.
Alpha-1 Antitrypsin Deficiency and COPD
Alpha-1 is the #1 genetic risk for COPD. AAT deficiency is a contributing cause in approximately 3% of COPD cases in the US.
Curated collection of alpha-1 antitrypsin (AAT) deficiency videos and downloads for healthcare professionals.
Of more than 900,000 COPD patients screened for alpha-1 over 10 years, 15% (>140,000 patients) had at least 1 deficient allele
Of more than 900,000 COPD patients screened for alpha-1 over 10 years, 15% (>140,000 patients) had at least 1 deficient allele
The most common mortality cause in patients with AAT deficiency is respiratory failure.
Consequences of AAT Deficiency
The most common mortality cause in patients with AAT deficiency is respiratory failure.
AlphaID cheek swab is a genetic test that screens for the 14 most prevalent mutations associated with alpha-1 antitrypsin (AAT) deficiency.
AlphaID cheek swab is a genetic test that screens for the 14 most prevalent mutations associated with alpha-1 antitrypsin (AAT) deficiency.
Support for Practices that Screen with AlphaID
The role of respiratory therapists, nurse practitioners and physician assistants in alpha-1 antitrypsin (AAT) deficiency diagnosis.
AAT deficiency is not rare; it is rarely diagnosed
Find out more about the estimated prevalence of AAT deficiency